Farlow MR

General

Full name : Farlow Martin R

First name : Martin R

Mail : Department of Neurology, Alzheimer's Disease and Memory Disorders Center, Baylor College of Medicine, Houston, TX 07730

Zip Code :

City :

Country : USA

Email :

Phone :

Fax :

Website :

Directory :

References (49)

Title : Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD - Pottier_2019_Acta.Neuropathol_137_879
Author(s) : Pottier C , Ren Y , Perkerson RB, 3rd , Baker M , Jenkins GD , van Blitterswijk M , DeJesus-Hernandez M , van Rooij JGJ , Murray ME , Christopher E , McDonnell SK , Fogarty Z , Batzler A , Tian S , Vicente CT , Matchett B , Karydas AM , Hsiung GR , Seelaar H , Mol MO , Finger EC , Graff C , Oijerstedt L , Neumann M , Heutink P , Synofzik M , Wilke C , Prudlo J , Rizzu P , Simon-Sanchez J , Edbauer D , Roeber S , Diehl-Schmid J , Evers BM , King A , Mesulam MM , Weintraub S , Geula C , Bieniek KF , Petrucelli L , Ahern GL , Reiman EM , Woodruff BK , Caselli RJ , Huey ED , Farlow MR , Grafman J , Mead S , Grinberg LT , Spina S , Grossman M , Irwin DJ , Lee EB , Suh E , Snowden J , Mann D , Ertekin-Taner N , Uitti RJ , Wszolek ZK , Josephs KA , Parisi JE , Knopman DS , Petersen RC , Hodges JR , Piguet O , Geier EG , Yokoyama JS , Rissman RA , Rogaeva E , Keith J , Zinman L , Tartaglia MC , Cairns NJ , Cruchaga C , Ghetti B , Kofler J , Lopez OL , Beach TG , Arzberger T , Herms J , Honig LS , Vonsattel JP , Halliday GM , Kwok JB , White CL, 3rd , Gearing M , Glass J , Rollinson S , Pickering-Brown S , Rohrer JD , Trojanowski JQ , Van Deerlin V , Bigio EH , Troakes C , Al-Sarraj S , Asmann Y , Miller BL , Graff-Radford NR , Boeve BF , Seeley WW , Mackenzie IRA , van Swieten JC , Dickson DW , Biernacka JM , Rademakers R
Ref : Acta Neuropathologica , 137 :879 , 2019
PubMedID: 30739198

Title : Revisiting the Cholinergic Hypothesis in Alzheimer's Disease: Emerging Evidence from Translational and Clinical Research - Hampel_2019_J.Prev.Alzheimers.Dis_6_2
Author(s) : Hampel H , Mesulam MM , Cuello AC , Khachaturian AS , Vergallo A , Farlow MR , Snyder PJ , Giacobini E , Khachaturian ZS
Ref : J Prev Alzheimers Dis , 6 :2 , 2019
PubMedID: 30569080

Title : The cholinergic system in the pathophysiology and treatment of Alzheimer's disease - Hampel_2018_Brain_141_1917
Author(s) : Hampel H , Mesulam MM , Cuello AC , Farlow MR , Giacobini E , Grossberg GT , Khachaturian AS , Vergallo A , Cavedo E , Snyder PJ , Khachaturian ZS
Ref : Brain , 141 :1917 , 2018
PubMedID: 29850777

Title : Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease - Chase_2017_Neurotherapeutics_14_405
Author(s) : Chase TN , Farlow MR , Clarence-Smith K
Ref : Neurotherapeutics , 14 :405 , 2017
PubMedID: 28138837

Title : Reviewing the role of donepezil in the treatment of Alzheimer's disease - Doody_2012_Curr.Alzheimer.Res_9_773
Author(s) : Doody RS , Cummings JL , Farlow MR
Ref : Curr Alzheimer Res , 9 :773 , 2012
PubMedID: 22175653

Title : Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy - Farlow_2011_Int.J.Geriatr.Psychiatry_26_1236
Author(s) : Farlow MR , Grossberg GT , Meng X , Olin J , Somogyi M
Ref : Int J Geriatr Psychiatry , 26 :1236 , 2011
PubMedID: 22068922

Title : Differences in medication use in the Alzheimer's disease neuroimaging initiative: analysis of baseline characteristics - Epstein_2010_Drugs.Aging_27_677
Author(s) : Epstein NU , Saykin AJ , Risacher SL , Gao S , Farlow MR
Ref : Drugs & Aging , 27 :677 , 2010
PubMedID: 20658795

Title : Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease - Farlow_2010_Am.J.Alzheimers.Dis.Other.Demen_25_347
Author(s) : Farlow MR , Cummings JL , Olin JT , Meng X
Ref : Am J Alzheimers Dis Other Demen , 25 :347 , 2010
PubMedID: 20392862

Title : Treatment options in Alzheimer's disease: maximizing benefit, managing expectations - Farlow_2008_Dement.Geriatr.Cogn.Disord_25_408
Author(s) : Farlow MR , Miller ML , Pejovic V
Ref : Dementia & Geriatric Cognitive Disorders , 25 :408 , 2008
PubMedID: 18391487

Title : Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease - Lane_2008_Pharmacogenet.Genomics_18_289
Author(s) : Lane R , Feldman HH , Meyer J , He Y , Ferris SH , Nordberg A , Darreh-Shori T , Soininen H , Pirttila T , Farlow MR , Sfikas N , Ballard C , Greig NH
Ref : Pharmacogenet Genomics , 18 :289 , 2008
PubMedID: 18334913

Title : Effective pharmacologic management of Alzheimer's disease - Farlow_2007_Am.J.Med_120_388
Author(s) : Farlow MR , Cummings JL
Ref : American Journal of Medicine , 120 :388 , 2007
PubMedID: 17466645

Title : Use of antidementia agents in vascular dementia: beyond Alzheimer disease - Farlow_2006_Mayo.Clin.Proc_81_1350
Author(s) : Farlow MR
Ref : Mayo Clin Proc , 81 :1350 , 2006
PubMedID: 17036561

Title : Recommendations for best practices in the treatment of Alzheimer's disease in managed care - Fillit_2006_Am.J.Geriatr.Pharmacother_4 Suppl A_S9
Author(s) : Fillit HM , Doody RS , Binaso K , Crooks GM , Ferris SH , Farlow MR , Leifer B , Mills C , Minkoff N , Orland B , Reichman WE , Salloway S
Ref : Am J Geriatr Pharmacother , 4 Suppl A :S9 , 2006
PubMedID: 17157793

Title : High levels of Alzheimer beta-amyloid precursor protein (APP) in children with severely autistic behavior and aggression - Sokol_2006_J.Child.Neurol_21_444
Author(s) : Sokol DK , Chen D , Farlow MR , Dunn DW , Maloney B , Zimmer JA , Lahiri DK
Ref : Journal of Child Neurology , 21 :444 , 2006
PubMedID: 16948926

Title : Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis - Farlow_2005_Dement.Geriatr.Cogn.Disord_20_192
Author(s) : Farlow MR , Small GW , Quarg P , Krause A
Ref : Dementia & Geriatric Cognitive Disorders , 20 :192 , 2005
PubMedID: 16088144

Title : The use of memantine in dementia with Lewy bodies - Sabbagh_2005_J.Alzheimers.Dis_7_285
Author(s) : Sabbagh MN , Hake AM , Ahmed S , Farlow MR
Ref : J Alzheimers Dis , 7 :285 , 2005
PubMedID: 16131729

Title : Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years - Farlow_2005_BMC.Geriatr_5_3
Author(s) : Farlow MR , Lilly ML
Ref : BMC Geriatr , 5 :3 , 2005
PubMedID: 15659242

Title : Cholinesterase inhibitors across stages of dementia and cognitive impairments in the elderly - Grossberg_2005_CNS.Spectr_10_1
Author(s) : Grossberg GT , Borson S , Kaufer DI , Farlow MR
Ref : CNS Spectr , 10 :1 , 2005
PubMedID: 15980818

Title : Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease - Lane_2005_J.Lipid.Res_46_949
Author(s) : Lane RM , Farlow MR
Ref : J Lipid Res , 46 :949 , 2005
PubMedID: 15716586

Title : Switching From Donepezil to Rivastigmine Is Well Tolerated: Results of an Open-Label Safety and Tolerability Study - Sadowsky_2005_Prim.Care.Companion.J.Clin.Psychiatry_7_43
Author(s) : Sadowsky CH , Farlow MR , Atkinson L , Steadman J , Koumaras B , Chen M , Mirski D
Ref : Prim Care Companion J Clin Psychiatry , 7 :43 , 2005
PubMedID: 15841194

Title : Poster (39) A new generation of cholinesterase inhibitors with amyloid-modifying properties. -
Author(s) : Lahiri DK , Ge YW , Sambamurti K , Utsuki T , Ingram DK , Farlow MR , Greig NH
Ref : In: Cholinesterases in the Second Millennium: Biomolecular and Pathological Aspects , (Inestrosa NC, Campos EO) P. Universidad Catolica de Chile-FONDAP Biomedicina :341 , 2004
PubMedID:

Title : Utilizing combination therapy in the treatment of Alzheimer's disease - Farlow_2004_Expert.Rev.Neurother_4_799
Author(s) : Farlow MR
Ref : Expert Rev Neurother , 4 :799 , 2004
PubMedID: 15853507

Title : Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial - Tariot_2004_JAMA_291_317
Author(s) : Tariot PN , Farlow MR , Grossberg GT , Graham SM , McDonald S , Gergel I
Ref : Jama , 291 :317 , 2004
PubMedID: 14734594

Title : Update on rivastigmine - Farlow_2003_Neurologist_9_230
Author(s) : Farlow MR
Ref : Neurologist , 9 :230 , 2003
PubMedID: 14587496

Title : A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease - Lahiri_2003_Curr.Drug.Targets_4_97
Author(s) : Lahiri DK , Farlow MR , Sambamurti K , Greig NH , Giacobini E , Schneider LS
Ref : Curr Drug Targets , 4 :97 , 2003
PubMedID: 12558063

Title : Review: cholinesterase inhibitors have a modest effect on neuropsychiatric and functional outcomes in Alzheimer's disease -
Author(s) : Lahiri DK , Farlow MR
Ref : Evid Based Ment Health , 6 :94 , 2003
PubMedID: 12893805

Title : Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial - Aisen_2003_JAMA_289_2819
Author(s) : Aisen PS , Schafer KA , Grundman M , Pfeiffer E , Sano M , Davis KL , Farlow MR , Jin S , Thomas RG , Thal LJ
Ref : Jama , 289 :2819 , 2003
PubMedID: 12783912

Title : Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors - Gauthier_2003_Curr.Med.Res.Opin_19_707
Author(s) : Gauthier S , Emre M , Farlow MR , Bullock R , Grossberg GT , Potkin SG
Ref : Curr Med Res Opin , 19 :707 , 2003
PubMedID: 14687441

Title : Clinical pharmacokinetics of galantamine - Farlow_2003_Clin.Pharmacokinet_42_1383
Author(s) : Farlow MR
Ref : Clinical Pharmacokinetics , 42 :1383 , 2003
PubMedID: 14674789

Title : Cholinesterase inhibitors: relating pharmacological properties to clinical profiles: Introduction -
Author(s) : Farlow MR
Ref : Int J Clin Pract Suppl , 127 :1 , 2002
PubMedID: 12139364

Title : Do cholinesterase inhibitors slow progression of Alzheimer's disease? - Farlow_2002_Int.J.Clin.Pract.Suppl_127_37
Author(s) : Farlow MR
Ref : Int J Clin Pract Suppl , 127 :37 , 2002
PubMedID: 12139366

Title : Nicotine reduces the secretion of Alzheimer's beta-amyloid precursor protein containing beta-amyloid peptide in the rat without altering synaptic proteins - Lahiri_2002_Ann.N.Y.Acad.Sci_965_364
Author(s) : Lahiri DK , Utsuki T , Chen D , Farlow MR , Shoaib M , Ingram DK , Greig NH
Ref : Annals of the New York Academy of Sciences , 965 :364 , 2002
PubMedID: 12105112

Title : Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression - Farlow_2001_Arch.Neurol_58_417
Author(s) : Farlow MR , Hake A , Messina J , Hartman R , Veach J , Anand R
Ref : Archives of Neurology , 58 :417 , 2001
PubMedID: 11255445

Title : Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine - Farlow_2001_Clin.Ther_23 Suppl A_A13
Author(s) : Farlow MR
Ref : Clin Ther , 23 Suppl A :A13 , 2001
PubMedID: 11396867

Title : New concepts in the drug therapy of Alzheimer's disease - Hake_2001_Expert.Opin.Pharmacother_2_1975
Author(s) : Hake AM , Farlow MR
Ref : Expert Opin Pharmacother , 2 :1975 , 2001
PubMedID: 11825329

Title : Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials - Farlow_2000_Dement.Geriatr.Cogn.Disord_11_202
Author(s) : Farlow MR , Cyrus PA
Ref : Dementia & Geriatric Cognitive Disorders , 11 :202 , 2000
PubMedID: 10867446

Title : Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease - Lahiri_2000_Acta.Neurol.Scand.Suppl_176_60
Author(s) : Lahiri DK , Farlow MR , Hintz N , Utsuki T , Greig NH
Ref : Acta Neurologica Scandinavica Supplementum , 176 :60 , 2000
PubMedID: 11273593

Title : Metrifonate treatment of AD: influence of APOE genotype - Farlow_1999_Neurology_53_2010
Author(s) : Farlow MR , Cyrus PA , Nadel A , Lahiri DK , Brashear A , Gulanski B
Ref : Neurology , 53 :2010 , 1999
PubMedID: 10599773

Title : Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease - Farlow_1998_Neurology_50_669
Author(s) : Farlow MR , Lahiri DK , Poirier J , Davignon J , Schneider L , Hui SL
Ref : Neurology , 50 :669 , 1998
PubMedID: 9521254

Title : A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group - Rogers_1998_Neurology_50_136
Author(s) : Rogers SL , Farlow MR , Doody RS , Mohs R , Friedhoff LT
Ref : Neurology , 50 :136 , 1998
PubMedID: 9443470

Title : The secretion of amyloid beta-peptides is inhibited in the tacrine-treated human neuroblastoma cells - Lahiri_1998_Brain.Res.Mol.Brain.Res_62_131
Author(s) : Lahiri DK , Farlow MR , Sambamurti K
Ref : Brain Research Mol Brain Res , 62 :131 , 1998
PubMedID: 9813282

Title : Pharmacologic treatment of cognition in Alzheimer's dementia - Farlow_1998_Neurology_51_S65
Author(s) : Farlow MR , Evans RM
Ref : Neurology , 51 :S65 , 1998
PubMedID: 9674761

Title : The effect of tacrine and leupeptin on the secretion of the beta- amyloid precursor protein in HeLa cells - Lahiri_1997_Life.Sci_61_1985
Author(s) : Lahiri DK , Farlow MR , Sambamurti K , Nall C
Ref : Life Sciences , 61 :1985 , 1997
PubMedID: 9366505

Title : Potential role for estrogen replacement in the treatment of Alzheimer's dementia - Schneider_1997_Am.J.Med_103_46S
Author(s) : Schneider LS , Farlow MR , Pogoda JM
Ref : American Journal of Medicine , 103 :46S , 1997
PubMedID: 9344406

Title : Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures - Lahiri_1997_Ann.N.Y.Acad.Sci_826_416
Author(s) : Lahiri DK , Farlow MR , Nurnberger JI, Jr. , Greig NH
Ref : Annals of the New York Academy of Sciences , 826 :416 , 1997
PubMedID: 9329715

Title : Apolipoprotein E genotype and gender influence response to tacrine therapy - Farlow_1996_Ann.N.Y.Acad.Sci_802_101
Author(s) : Farlow MR , Lahiri DK , Poirier J , Davignon J , Hui S
Ref : Annals of the New York Academy of Sciences , 802 :101 , 1996
PubMedID: 8993489

Title : Differential effect of tacrine and physostigmine on the secretion of the beta-amyloid precursor protein in cell lines - Lahiri_1996_J.Mol.Neurosci_7_41
Author(s) : Lahiri DK , Farlow MR
Ref : Journal of Molecular Neuroscience , 7 :41 , 1996
PubMedID: 8835781

Title : Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease - Schneider_1996_Neurology_46_1580
Author(s) : Schneider LS , Farlow MR , Henderson VW , Pogoda JM
Ref : Neurology , 46 :1580 , 1996
PubMedID: 8649552

Title : Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines - Lahiri_1994_J.Neurosci.Res_37_777
Author(s) : Lahiri DK , Lewis S , Farlow MR
Ref : Journal of Neuroscience Research , 37 :777 , 1994
PubMedID: 8046778